IMC001, an autologous CAR-T cell therapy targeting EpCAM, is currently in a Phase I/IIa clinical trial sponsored by Suzhou Immunofoco Biotechnology Co., Ltd. This therapy aims to address advanced epithelial solid tumors, including gastric, breast, biliary, ovarian, colorectal, and pancreatic cancers. The market for CAR-T therapies is rapidly expanding, particularly in oncology, with increasing competition from established players and emerging biotech firms. The successful demonstration of safety and efficacy in this trial could position Immunofoco favorably within the CAR-T landscape, potentially leading to partnerships or acquisition interest from larger pharmaceutical companies. However, the trial's reliance on a specific patient population with advanced disease and prior treatment failures may limit the addressable market size. Diligence should focus on regulatory pathways and reimbursement strategies for CAR-T therapies in the targeted indications.